Blood Thinner May Slow Cognitive Decline in Alzheimer’s Patients With AFib

Recent research from Sweden indicates that a class of blood thinners known as non-vitamin K antagonist oral anticoagulants (NOACs) may play a crucial role in slowing cognitive decline among Alzheimer’s patients who also suffer from atrial fibrillation (AFib). This study suggests that these modern blood thinners not only serve to prevent strokes but may also have beneficial effects on brain health.

Alzheimer’s patients with AFib are at an increased risk for “silent strokes,” which can lead to significant brain damage. The formation of blood clots in the heart can result in these strokes, making effective anticoagulation therapy essential. NOACs are believed to be more effective and safer than traditional blood thinners like warfarin, which have been commonly used in these situations.

The findings were published in the European Heart Journal on August 12, highlighting the potential cognitive advantages of NOACs. Maria Eriksdotter, a professor at the Karolinska Institutet in Stockholm and a senior consultant in geriatric medicine, noted that improved blood flow and reduced small-scale brain damage could contribute to better cognitive outcomes in patients receiving NOAC treatment.

The study analyzed data from over 7,300 Alzheimer’s patients who were also diagnosed with AFib. Researchers utilized various national Swedish registries that provided comprehensive information on dementia diagnoses, cognitive assessments, hospital visits, and medications. They assessed cognitive function using the Mini-Mental State Examination (MMSE), a standard test for evaluating memory and cognitive skills.

Participants were divided into three groups based on their use of blood thinners: those not taking any anticoagulants, those on warfarin, and those using NOACs. Researchers tracked changes in cognitive function over a span of up to five years, accounting for various health factors to ensure fair comparisons.

The results were promising; individuals taking NOACs exhibited a slower rate of cognitive decline compared to those on warfarin or not on any blood thinner. While warfarin users did not show significant differences in cognitive decline from non-users, those on NOACs experienced a modest yet meaningful improvement in cognitive function. Additionally, NOAC users had lower incidences of stroke, death, and fractures without increasing the risk of major bleeding, a common concern with anticoagulant therapy.

The study indicates that NOACs could provide significant advantages over warfarin, especially for individuals with both AFib and Alzheimer’s disease. The ease of use of these newer anticoagulants may lead to better adherence in patients who struggle with cognitive impairments, making NOACs a more suitable option.

According to Dr. Bhaskar Semitha, a cardiothoracic surgeon who was not involved in the study, the benefits of NOACs in preventing silent strokes are particularly important. With AFib causing blood to pool and form micro-clots that can damage brain tissue, NOACs may help safeguard healthy brain function without the severe bleeding risks associated with older blood thinners.

As a result of these findings, there may be a shift in how doctors prescribe anticoagulants for older patients. With the potential for NOACs to preserve cognitive function, healthcare providers may increasingly view them as a dual-purpose treatment, benefiting both heart health and brain health. This could foster greater collaboration between cardiologists and neurologists, ultimately improving care for patients with overlapping cardiovascular and neurological conditions.